



Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

| | |
|----------------------|-----------------------------|
| Application Number | 10/077,154 |
| Filing Date | February 15, 2002 |
| First Named Inventor | Timothy J. Martins |
| Group Art Unit | 1626 |
| Examiner Name | Unassigned E. <i>Sackey</i> |

Attorney Docket Number 27866/38184

TECH CENTER
JUN 1
600/2002

RECEIVED
JUN 1
2002

| Examiner Initials* | Cite No. | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document |
|--------------------|----------|-----------------------------|--------------------------------|--|
| | | Number-Kind Code (if known) | | |
| <i>B</i> | | 3,935,217 | 01/27/76 | Nakanishi et al. |
| <i>B</i> | | 5,665,754 | 09/09/97 | Feldman et al. |
| <i>B</i> | | 5,998,428 | 12/07/99 | Barnette et al. |

| Examiner Initials* | Cite No. | Foreign Patent Document | Publication Date MM-DD-YYYY |
|--------------------|----------|-------------------------|--------------------------------|
| | | | MM-DD-YYYY |
| <i>B</i> | | 0 671 389 (EPO) | 09/13/95 |
| <i>B</i> | | WO 92/19594 (PCT) | 11/12/92 |
| <i>B</i> | | WO 95/08534 (PCT) | 03/30/95 |
| <i>B</i> | | WO 97/25312 (PCT) | 07/17/97 |

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|-------------------|----------|--|
| <i>B</i> | | J.E. Schultz et al., <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> , 333, pp. 23-30 (1986). |
| | | Z. Ma et al., <i>Tetrahedron: Asymmetry</i> , Vol. 8, No. 6, pp. 883-887 (1997). |
| | | A. Robichaud et al., <i>Neuropharmacology</i> , 38, pp. 289-297 (1999). |
| | | R.A. Allen et al., <i>Biochemical Pharmacology</i> , Vol. 57, pp. 1375-1382 (1999). |
| | | J. Beavo et al., "Cyclic nucleotide phosphodiesterases: Structure, regulation and drug action," Wiley and Sons, Chichester, pp. 3-14 (1990). |
| | | T.J. Torphy et al., <i>Drug News and Perspectives</i> , 6, pp. 203-214 (1993). |
| | | M.A. Giembycz et al., <i>Clin. Exp. Allergy</i> , 22, pp. 337-344 (1992). |
| | | J. Semmler et al., <i>Int. J. Immunopharmacol.</i> , 15, pp. 409-413 (1993). |
| | | K.L. Molnar-Kimber et al., <i>Mediators of Inflammation</i> , 1, pp. 411-417 (1992). |
| | | M.W. Verghese et al., <i>J. Mol. Cell Cardiol.</i> , 21 (Suppl. 2), S61 (1989). |
| | | C.P. Nielson et al., <i>J. Allergy Immunol.</i> , 86, pp. 801-808 (1990). |
| | | P.T. Peachell et al., <i>J. Immunol.</i> , 148, pp. 2503-2510 (1992). |
| | | G. Dent et al., <i>J. Pharmacol.</i> , 103, pp. 1339-1346 (1991). |
| | | S.A. Robicsek et al., <i>Biochem. Pharmacol.</i> , 42, pp. 869-877 (1991). |
| | | H.S. Dhillon et al., <i>J. Neurotrauma</i> , 12, pp. 1035-1043 (1995). |
| | | N. Suttorp et al., <i>J. Clin. Invest.</i> , 91, pp. 1421-1428 (1993). |
| | | M.R. Bristow et al., <i>Circulation</i> , 97, pp. 1340-1341 (1998). |
| <i>B</i> | | G. Poli et al., <i>Proc. Natl. Acad. Sci. USA</i> , 87, pp. 782-785 (1990). |

| | | | |
|--------------------|--------------------|-----------------|--------|
| Examiner Signature | <i>Amal Sackey</i> | Date Considered | 1/8/03 |
|--------------------|--------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 11 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

| Complete if Known | |
|------------------------|----------------------|
| Application Number | 10/077,154 |
| Filing Date | February 15, 2002 |
| First Named Inventor | Timothy J. Martins |
| Group Art Unit | 1626 |
| Examiner Name | Unassigned E. Sackey |
| Attorney Docket Number | 27866/38184 |

RECEIVED
JUN 13 2002
EX-2002
EPO

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|-------------------|----------|--|
| ES | | P. Orosz et al., <i>J. Exp. Med.</i> , 177, pp. 1391-1398 (1993). |
| | | M. Mentz et al., <i>Blood</i> , 88, pp. 2172-2182 (1996). |
| | | S. Takeda et al., <i>Kidney Int.</i> , 37, p. 362 (1990). |
| | | D. Chabardea et al., <i>Kidney Int.</i> , 35, p. 494 (1989). |
| | | C.D. Nicholson, <i>Psychopharmacology</i> , 101, p. 147 (1990). |
| | | F. Eckmann et al., <i>Curr. Ther. Res.</i> , 43, p. 291 (1988). |
| | | A. Kłodzinska et al., <i>Neuropharmacology</i> , 38, p. 1831 (1991). |
| | | H. Kato et al., <i>Eur. J. Pharmacol.</i> , 272, p. 107 (1995). |
| | | G. Gardos et al., <i>J. Clin. Pharmacol.</i> , 16, p. 304 (1976). |
| | | I. Shoulson et al., <i>Neurology</i> , 25, p. 722 (1975). |
| | | T. Hayakawa et al., <i>Clin. Exp. Pharmacol. Physiol.</i> , 26, p. 421 (1999). |
| | | R.D. Porsolt et al., <i>Eur. J. Pharmacol.</i> , 47, p. 379 (1978). |
| | | R.D. Porsolt et al., <i>Eur. J. Pharmacol.</i> , 57, p. 431 (1979). |
| | | L. Steru, <i>Psychopharmacology</i> , 85, p. 376 (1985). |
| | | M. Takahashi, <i>J. Neuroscience</i> , 19, p. 610 (1999). |
| | | D. Pinsky et al., <i>J. Clin. Invest.</i> , 92, pp. 2994-3002 (1993). |
| ES | | <i>Antidepressants: neurochemical, behavioral and clinical perspectives</i> , Enna, Malick, and Richelson, eds., Raven Press, pp. 121-139 (1981). |

| | | | |
|--------------------|---------------------|-----------------|--------|
| Examiner Signature | <i>Terah Sackey</i> | Date Considered | 1/8/03 |
|--------------------|---------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.